{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-004227","form_type":"8-K","ticker":"CERS","cik":"0001020214","company_name":"CERUS CORP","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.525994+00:00","generated_at":"2026-06-20T17:25:41.596054+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Cerus reports preliminary 2022 product revenue of $162M, up 24% YoY, and guides 2023 revenue $165-170M","bullets":["Preliminary Q4 2022 product revenue $44.0M, up 10% from Q4 2021.","Full-year 2022 product revenue $162.0M, at top end of guidance, up 24% year-over-year.","2023 product revenue guidance range of $165-170M, citing macroeconomic uncertainty and FX headwinds.","CEO Obi Greenman notes consistent commercial execution and growing demand for INTERCEPT Blood System in U.S.","Company expects 2023 to be a bridge year with uncertainty most acute in Q1."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-004227","json":"https://secwatch.observer/filing/0001193125-23-004227.json","markdown":"https://secwatch.observer/filing/0001193125-23-004227.md","text":"https://secwatch.observer/filing/0001193125-23-004227.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1020214/000119312523004227/0001193125-23-004227-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1020214/000119312523004227/d426660d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T17:25:41.596054+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a32defc92df52093e48ff42412d8da055cdd6ecc","claim":"CERUS CORP reported the fourth quarter and fiscal year ended December 31, 2022 results: revenue $44.0 million. Guidance initiated.","evidence_excerpt":"Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2022 Product Revenue and Provides Business Update Preliminary Fourth Quarter and Full-Year 2022 Product Revenues of $44.0 million and $162.0 million reflecting year-over-year growth of 10% and 24%, respectively","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1020214/000119312523004227/0001193125-23-004227-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and fiscal year ended December 31, 2022"},{"label":"Revenue","value":"$44.0 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}